Radiofrequency Ablation Devices Market Size Worth $7,711.72 Million, Globally, by 2027 at 11.5% CAGR - Exclusive Report by The Insight Partners
December 16, 2021 07:41 ET
|
The Insight Partners
New York, Dec. 16, 2021 (GLOBE NEWSWIRE) -- According to the new market research report "Radiofrequency Ablation Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product...
Bone Tumor Ablation Devices Market size worth $ 344.89 Million, Globally, by 2028 at 8.21% CAGR: Verified Market Research®
November 15, 2021 11:15 ET
|
Verified Market Research
Jersey City, New Jersey, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Bone Tumor Ablation Devices Market” By End User (Hospitals, Ambulatory Surgical...
Celsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study
July 13, 2020 08:30 ET
|
Celsion CORP
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion...
Principal Investigator Professor Riccardo Lencioni Presents Celsion ThermoDox® Trial Data at SPECTRUM 2020 Interventional Oncology Conference
February 04, 2020 08:30 ET
|
Celsion CORP
Company reaffirms its projection for second pre-planned interim efficacy analysis for Phase III OPTIMA Study in the second quarter of 2020 LAWRENCEVILLE, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) --...
Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference
September 23, 2019 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
August 05, 2019 09:00 ET
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
Radiofrequency Ablation Devices Market Size Worth Around USD 6.2 billion by 2026: Acumen Research and Consulting
April 09, 2019 10:00 ET
|
Acumen Research and Consulting
LOS ANGELES, April 09, 2019 (GLOBE NEWSWIRE) -- The global Radiofrequency Ablation Devices market is forecasted to grow at a stable CAGR around 11% during the forecast period 2018 to 2026 and reach...